Centermed Sp. z o.o.

Lublin 16 trials 4 recruiting

16 Registered trials

4 Currently recruiting

Organisation

Centermed Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100043448

Address

Ul. Wojciecha Bandrowskiego 16 A, 33-100, Poland

Departments

5704: CENTERMED BANDROWSKIEGO
5717: CENTERMED BANDROWSKIEGO
Allergology
Cardiology
CenterMed Bandrowskiego
Centermed Lublin
Centermed Sp. z o.o.
n/a
NA
No Department

Clinical trials at this site (16)

Search interface

Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending

2023-507427-28-00 seasonal allergic rhinitis and/or rhinoconjunctivitis 5
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting

2025-523180-38-00 Uncontrolled Moderate to Severe Eosinophilic Asthma 4 2026-05-21
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma Recruiting

2022-502984-39-00 Severe Uncontrolled Asthma Asthma (an illness that caus 5 2023-12-13
A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high… Recruiting

2022-501344-14-00 Paediatric Patients with Severe Eosinophilic Asthma Ast 5 2023-06-05
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W… Ended

2023-507206-13-00 Type 2 Diabetes 5 2024-03-14
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended

2023-503657-35-00 Obesity 5 2023-10-10
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12
A Study of LY3540378 in Participants with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) Ended

2023-505902-40-00 Heart Failure with Preserved Ejection Fraction 4 2023-03-28
"A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended

2023-505787-11-00 Severe and inadequately controlled asthma 5 2021-04-29
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24